Glioblastoma News and Research

RSS

Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.

International researchers find how brain cancer cells survive and drive tumor growth

An international team of researchers - led by principal investigator Paul S. Mischel, MD, a member of the Ludwig Institute for Cancer Research and professor in the Department of Pathology at the University of California, San Diego School of Medicine - has found that a singular gene mutation helps brain cancer cells to not just survive, but grow tumors rapidly by altering the splicing of genes that control cellular metabolism.

1 Jun 2013

Glioblastoma patients treated with bevacizumab have deterioration in neurocognitive function

Many glioblastoma patients treated with bevacizumab (Avastin-) have significant deterioration in neurocognitive function, symptoms and quality of life. Not only that, the changes often predict treatment outcomes, according to new research from The University of Texas MD Anderson Cancer Center.

1 Jun 2013

Research gives hope: Patients' immune system could fight glioblastoma multiforme

Research at Lund University in Sweden gives hope that one of the most serious types of brain tumour, glioblastoma multiforme, could be fought by the patients' own immune system.

31 May 2013

Physicists demonstrate effect of cold atmospheric plasma, chemo therapy on brain tumour cells

For the first time, physicists from the Max Planck Institute for Extraterrestrial Physics (MPE), biologists and physicians demonstrated the synergistic effect of cold atmospheric plasma - a partly ionized gas - and chemo therapy on aggressive brain tumour cells.

23 May 2013

Poliovirus vaccine study shows encouraging results in glioblastoma patients

An attack on glioblastoma brain tumor cells that uses a modified poliovirus is showing encouraging results in an early study to establish the proper dose level, researchers at Duke Cancer Institute report.

22 May 2013

NW Bio starts Phase III clinical trial with DCVax-L for brain cancer at King's College Hospital in UK

Northwest Biotherapeutics, a biotechnology company developing DCVax-L personalized immune therapies for solid tumor cancers, today announced that its Phase III clinical trial with DCVax-L for brain cancer has been initiated at King's College Hospital in the UK.

17 May 2013

Novel drug may increase the effectiveness of radiation therapy for brain cancer

A novel drug may help increase the effectiveness of radiation therapy for the most deadly form of brain cancer, report scientists at Virginia Commonwealth University Massey Cancer Center. In mouse models of human glioblastoma multiforme (GBM), the new drug helped significantly extend survival when used in combination with radiation therapy.

15 May 2013

Drug resistant brain tumors: an interview with Prof. Mischel, Ludwig Institute for Cancer Research and Prof. Bensinger, University of California

In cancer, mutations in proteins that control cell growth are common, leading to unrestrained cellular proliferation and tumor formation.

9 May 2013

Details about genomic landscapes of AML and endometrial cancer revealed

Two studies from The Cancer Genome Atlas program reveal details about the genomic landscapes of acute myeloid leukemia and endometrial cancer.

2 May 2013

Neuralstem gets approval from FDA for dosing cohort patients in NSI-189 Phase Ib in MDD treatment

Neuralstem, Inc. announced that it has received approval from the Food and Drug Administration (FDA) to begin dosing the third and final cohort of patients in its ongoing Phase Ib to test the safety of NSI-189 in the treatment of major depressive disorder (MDD).

26 Apr 2013

New collaboration to expand vaccine approaches for melanoma

Aduro BioTech, Inc. announces a collaboration with Charles G. Drake, M.D., Ph.D., Associate Professor of Oncology, Immunology and Urology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center to evaluate the therapeutic approach of anti-PD-1 in combination with one or both of Aduro's vaccine technologies based on live, attenuated Listeria monocytogenes and STING-activating adjuvants.

23 Apr 2013

Study identifies potential drug targets that interfere with cancer metabolism

A massive study analyzing gene expression data from 22 tumor types has identified multiple metabolic expression changes associated with cancer.

22 Apr 2013

GBM brain cancer patient treated with DCVax-L celebrates 10th anniversary of cancer-free survival

Northwest Biotherapeutics, a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, announced today that Brad Silver, an All American swimming and water polo athlete who was diagnosed with Glioblastoma multiforme brain cancer in late 2002, and was treated with DCVax-L in March of 2003, just celebrated the 10th anniversary of his continued cancer-free survival.

19 Apr 2013

Study reports role of cytochrome c oxidase as prognostic marker in GBM patients' tumor tissues

Researchers may have discovered a more accurate way to predict how long patients with the deadliest form of brain cancer will live, according to an analysis by researchers from the University of Alabama at Birmingham published today in the journal PLOS ONE.

11 Apr 2013

DelMar Pharmaceuticals reports positive results from VAL-083 Phase I/II clinical trial in patients with GBM

DelMar Pharmaceuticals, Inc. today announced additional positive interim data from an ongoing Phase I/II clinical trial of VAL-083 in patients with recurrent glioblastoma multiforme (GBM) or progressive secondary brain tumor.

11 Apr 2013

Nano-sized EVs play role in cancer growth and survival

The recent discovery of circulating "nano-sized extracellular vesicles" (EVs) carrying proteins and nucleic acids derived from brain tumors may lead to exciting new avenues for brain cancer diagnosis, monitoring, and treatment, according to a special article in the April issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

9 Apr 2013

Exosome profiling of mRNAs and miRNAs in serum samples presented at AACR meeting

Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostics for use in personalized medicine, today announced that the company is presenting a late-breaking abstract at the AACR Annual Meeting 2013, in Washington D.C.

9 Apr 2013

Researchers explore how blocking EGFR changes signaling in glioblastoma cells

Proteins that control cell growth are often mutated in cancer, and their aberrant signaling drives the wild proliferation of cells that gives rise to tumors. One such protein, the epidermal growth factor receptor, fuels a wide variety of cancers-including a highly malignant brain cancer known as glioblastoma.

9 Apr 2013

Mammalian target of rapamycin (mTOR) pathway: an interview with Dr. Paul Mischel, Ludwig Institute for Cancer Research

The mammalian target of rapamycin, mTOR is a central integrator of the cell that coordinates growth factor receptor signaling with energy and nutrient status to control a wide array of activities, including the regulation of cellular proliferation and survival.

9 Apr 2013

ARIAD Pharmaceuticals presents preclinical data on ponatinib at AACR Annual Meeting 2013

ARIAD Pharmaceuticals, Inc. today announced the presentation of preclinical data on ponatinib (Iclusig) , at the American Association for Cancer Research Annual Meeting 2013, in Washington.

9 Apr 2013

Glioblastoma News and Research

Further Reading

International researchers find how brain cancer cells survive and drive tumor growth

Glioblastoma patients treated with bevacizumab have deterioration in neurocognitive function

Research gives hope: Patients' immune system could fight glioblastoma multiforme

Physicists demonstrate effect of cold atmospheric plasma, chemo therapy on brain tumour cells

Poliovirus vaccine study shows encouraging results in glioblastoma patients

NW Bio starts Phase III clinical trial with DCVax-L for brain cancer at King's College Hospital in UK

Novel drug may increase the effectiveness of radiation therapy for brain cancer

Drug resistant brain tumors: an interview with Prof. Mischel, Ludwig Institute for Cancer Research and Prof. Bensinger, University of California

Details about genomic landscapes of AML and endometrial cancer revealed

Neuralstem gets approval from FDA for dosing cohort patients in NSI-189 Phase Ib in MDD treatment

New collaboration to expand vaccine approaches for melanoma

Study identifies potential drug targets that interfere with cancer metabolism

GBM brain cancer patient treated with DCVax-L celebrates 10th anniversary of cancer-free survival

Study reports role of cytochrome c oxidase as prognostic marker in GBM patients' tumor tissues

DelMar Pharmaceuticals reports positive results from VAL-083 Phase I/II clinical trial in patients with GBM

Nano-sized EVs play role in cancer growth and survival

Exosome profiling of mRNAs and miRNAs in serum samples presented at AACR meeting

Researchers explore how blocking EGFR changes signaling in glioblastoma cells

Mammalian target of rapamycin (mTOR) pathway: an interview with Dr. Paul Mischel, Ludwig Institute for Cancer Research

ARIAD Pharmaceuticals presents preclinical data on ponatinib at AACR Annual Meeting 2013

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News